About NeoPhore
NeoPhore is a company based in Cambridge (United Kingdom) founded in 2017 by Chris Torrance, Alberto Bardelli, and Giovanni Germano. It operates as a HealthTech. NeoPhore has raised $44.56 million across 5 funding rounds from investors including Bristol-Myers Squibb, Liftt and Sixth Element Capital. The company has 10 employees as of April 30, 2022. NeoPhore offers products and services including Small Molecule Drugs. NeoPhore operates in a competitive market with competitors including Metabolon, TScan Therapeutics, Lyell Immunopharma, Maze Therapeutics and Hummingbird Bioscience, among others.
- Headquarter Cambridge, United Kingdom
- Employees 10 as on 30 Apr, 2022
- Founders Chris Torrance, Alberto Bardelli, Giovanni Germano
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neophore Limited
- Date of Incorporation 09 May, 2017
- Jurisdiction ALTRINCHAM, CHESHIRE, UNITED KINGDOM
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$44.56 M (USD)
in 5 rounds
-
Latest Funding Round
$12.2 M (USD), Series B
Feb 01, 2024
-
Investors
Bristol-Myers Squibb
& 10 more
-
Employee Count
10
as on Apr 30, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NeoPhore
NeoPhore offers a comprehensive portfolio of products and services, including Small Molecule Drugs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Small molecule drugs are developed for cancer neoantigen evolution.
Unlock access to complete
Unlock access to complete
Funding Insights of NeoPhore
NeoPhore has successfully raised a total of $44.56M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $12.2 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $12.2M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2024 | Amount | Series B - NeoPhore | Valuation | Sixth Element Capital | |
| Jan, 2023 | Amount | Series B - NeoPhore | Valuation |
investors |
|
| Mar, 2021 | Amount | Series B - NeoPhore | Valuation | Claris Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in NeoPhore
NeoPhore has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Liftt and Sixth Element Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Claris Ventures is engaged in early-stage biotech venture investments.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by NeoPhore
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - NeoPhore
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neophore Comparisons
Competitors of NeoPhore
NeoPhore operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, TScan Therapeutics, Lyell Immunopharma, Maze Therapeutics and Hummingbird Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neophore
Frequently Asked Questions about NeoPhore
When was NeoPhore founded?
NeoPhore was founded in 2017.
Where is NeoPhore located?
NeoPhore is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Is NeoPhore a funded company?
NeoPhore is a funded company, having raised a total of $44.56M across 5 funding rounds to date. The company's 1st funding round was a Series B of $21.02M, raised on Nov 06, 2017.
How many employees does NeoPhore have?
As of Apr 30, 2022, the latest employee count at NeoPhore is 10.
What does NeoPhore do?
NeoPhore is engaged in the discovery and design of small molecule drugs targeting cancer neoantigen evolution. The company aims to develop effective and well-tolerated medicines as part of next-generation cancer immunotherapies. Solutions are designed to stimulate immunity directly at the core of cancer, addressing cancers lacking DNA mismatch repair genes. The approach is centered on creating robust and sustained immune responses in the healthcare sector, specifically within biotechnology and cancer treatment.
Who are the top competitors of NeoPhore?
NeoPhore's top competitors include Hummingbird Bioscience, Lyell Immunopharma and Maze Therapeutics.
What products or services does NeoPhore offer?
NeoPhore offers Small Molecule Drugs.
Who are NeoPhore's investors?
NeoPhore has 11 investors. Key investors include Bristol-Myers Squibb, Liftt, Sixth Element Capital, Claris Ventures, and Astellas Venture Management.